EX3 Investigating Time to Next Treatment As a Surrogate Endpoint for Overall Survival in Previously Untreated Intermediate- to Poor-Risk Advanced Renal Cell Carcinoma Patients: An Insight from the Phase III CheckMate-214
Abstract
Authors
S. Branchoux C.L. Sofeu M. Kurt A.F. Gaudin A. Italiano V. Rondeau C. Bellera